Similar articles

• Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication.

  Klutke CG, Burgio KL, Wyman JF, Guan Z, Sun F, Berriman S, Bavendam T. Klutke CG, et al. J Urol. 2009 Jun;181(6):2599-607. doi: 10.1016/j.juro.2009.02.028. Epub 2009 Apr 16. J Urol. 2009. PMID: 19375110
• Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.

  Rovner ES, Kreder K, Sussman DO, Kaplan SA, Carlsson M, Bavendam T, Guan Z. Rovner ES, et al. J Urol. 2008 Sep;180(3):1034-41. doi: 10.1016/j.juro.2008.05.050. Epub 2008 Jul 17. J Urol. 2008. PMID: 18639297 Clinical Trial.
• Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.

  Peters KM, Macdiarmid SA, Wooldridge LS, Leong FC, Shobeiri SA, Rovner ES, Siegel SW, Tate SB, Jarnagin BK, Rosenblatt PL, Feagins BA. Peters KM, et al. J Urol. 2009 Sep;182(3):1055-61. doi: 10.1016/j.juro.2009.05.045. Epub 2009 Jul 18. J Urol. 2009. PMID: 19616802 Clinical Trial.
• Tolterodine for the treatment of overactive bladder.

  Salvatore S, Serati M, Bolis P. Salvatore S, et al. Expert Opin Pharmacother. 2008 May;9(7):1249-55. doi: 10.1517/14656566.9.7.1249. Expert Opin Pharmacother. 2008. PMID: 18422481 Review.
• Tolterodine for treatment of overactive bladder.

  Kanofsky JA, Nitti VW. Kanofsky JA, et al. Urol Clin North Am. 2006 Nov;33(4):447-53, viii. doi: 10.1016/j.ucl.2006.06.004. Urol Clin North Am. 2006. PMID: 17011380 Review.